These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26290435)

  • 41. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
    Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus.
    Saidoune F; Even G; Lamri Y; Chezel J; Gaston AT; Escoubet B; Papo T; Charles N; Nicoletti A; Sacre K
    Arthritis Rheumatol; 2021 Feb; 73(2):255-264. PubMed ID: 32783382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
    Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
    Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
    Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The rationale for BAFF inhibition in systemic lupus erythematosus.
    Davidson A
    Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials.
    Abuqayyas L; Chen PW; Dos Santos MT; Parnes JR; Doshi S; Dutta S; Houk BE
    Clin Pharmacol Ther; 2023 Aug; 114(2):371-380. PubMed ID: 37150935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL/lpr mice.
    Yu C; Chen S; Zhou B; Zhang H; Su X; Luo Y; Yang L
    Mol Immunol; 2021 Jan; 129():1-11. PubMed ID: 33254074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
    Hartmann S; Biliouris K; Naik H; Rabah D; Stevenson L; Shen C; Nestorov IA; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):255-266. PubMed ID: 32335844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).
    Isenberg D; Gordon C; Licu D; Copt S; Rossi CP; Wofsy D
    Ann Rheum Dis; 2015 Nov; 74(11):2006-15. PubMed ID: 24951103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
    Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials.
    Rovin BH; Dooley MA; Radhakrishnan J; Ginzler EM; Forrester TD; Anderson PW
    Lupus; 2016 Dec; 25(14):1597-1601. PubMed ID: 27220348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
    Wallace DJ; Strand V; Merrill JT; Popa S; Spindler AJ; Eimon A; Petri M; Smolen JS; Wajdula J; Christensen J; Li C; Diehl A; Vincent MS; Beebe J; Healey P; Sridharan S
    Ann Rheum Dis; 2017 Mar; 76(3):534-542. PubMed ID: 27672124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB
    Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.